FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547286628> ?p ?o ?g. }

• W2547286628 abstract "Abstract Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis and increased risk of transformation to acute myeloid leukemia (AML). The identification of genes and cellular pathways active in leukemia cells but not in normal hematopoietic stem/progenitor cells (HSC) may help to understand the key steps in the MDS and AML pathogenesis and lead to new approaches to further enhance the treatment of both diseases, considered incurable with non-transplantation therapy. Src kinase family (SFK) is a central mediator in multiple oncogenic signaling pathways and some SFK members (Hck, Lyn, Fgr, Fyn) had previously been described as overexpressed or activated in leukemic cells. However, to this moment, the role of hematopoietic cell kinase (HCK), the unique SFK member restricted expressed in hematopoietic cells, had not been characterized in MDS and AML pathogenesis as well as in HSC. In order to better understand the HCK importance in hematopoiesis, we used lentiviral shRNA vectors to knockdown the HCK expression in primary human CD34+ HSC. The HCK levels were reduced in approximately 70-80% (shHCK) compared to the control lentiviral shRNA (shControl-GFP). To promote erythroid differentiation, human CD34+ transduced cells were grown in methylcellulose for 7 days and in liquid media for another 6 days. During this experiment, shHCK cells showed decreased cell viability (fold change compared to shControl-GFP = 0.55, P<.0001, n=3) combined with an increase in CD71+ expression (fold change compared to shControl-GFP = 3, P<.01, n=3), indicating a delay in erythroid differentiation. As expected, shControl-GFP cells showed a decreased GATA1 expression during erythroid differentiation. Meanwhile, shHCK cells did not modulate GATA1 expression. Interestingly, without any stimulus, HCK knockdown in CD34+ cells significantly decreased apoptosis (AnnexinV+ cells) compared to shControl-GFP (fold change = 0.52, P<.01, n=4). Attempts have been made to overexpress HCK in CD34+ HSC, however more than 80% cells were apoptotic and further assays were not possible. Thus, in HSC, HCK participates of erythroid differentiation and apoptosis signaling. According to the HCK importance on HSC and that SFK inhibitors are undergoing early phase clinical testing, a specific inhibitory activity compound for HCK, named iHCK-37, had been developed by Dr Maurizzio Botta. We tested this compound on primary normal human CD34+ cells originated from healthy donors bone marrow samples and also from cord blood units. The iHCK-37 treatment did not change proliferation, survival and death of these normal CD34+ cells. Conversely, MDS and AML CD34+ cells treated with the same drug exhibited a dose-dependent growth inhibition. Likewise, following iHCK-37 treatment of MDS and AML total bone marrow mononuclear cells, the BFU-E and CFUs colony numbers were significantly decreased compared to untreated cells (vehicle). We also observed a potent in vitro antiproliferative activity of iHCK-37 against a panel of leukemia cell lines, with uM IC50 values in AML (5.0 - 5.8uM) and chronic myeloid leukemia (9.1 - 19.2uM). In addition, the combinatory in vitro treatment of iHCK-37 and 5-Azacitidine (Aza) also demonstrated additive effects relative to either drug alone. Interestingly, iHCK-37 or iHCK-37 plus Aza treatments of dysplastic and leukemia cells enhanced apoptosis and resulted in increased BAX and reduced BCL-XL protein levels. This result could be clinically relevant for MDS, as Aza is the only treatment available for higher-risk MDS, but with low response rates and frequent induced resistance and refractoriness over time. In summary, we herein have shown that HCK mRNA knockdown of normal CD34+ cells resulted in growth inhibition, decreased cell death and reduced erythroid differentiation, suggesting that HCK is essential for normal hematopoiesis. We presume that the deregulation of HCK pathway in leukemic cells might be crucial for MDS and AML pathogenesis. On the other hand, the inhibition of HCK protein activity with a specific inhibitor was able to restore the apoptotic pathways of leukemic cells, acting on cancer cells without alter any signaling of normal cells. Moreover, the specific inhibitor may have antineoplastic effect that can even be additive to current available drugs. Our study adds new insights to the role of HCK in MDS and AML as well as into potential new anticancer treatment strategies. Disclosures No relevant conflicts of interest to declare." @default.
• W2547286628 created "2016-11-11" @default.
• W2547286628 creator A5005491305 @default.
• W2547286628 creator A5010109904 @default.
• W2547286628 creator A5021576578 @default.
• W2547286628 creator A5037030579 @default.
• W2547286628 creator A5037865344 @default.
• W2547286628 creator A5052529953 @default.
• W2547286628 creator A5061724535 @default.
• W2547286628 creator A5062183952 @default.
• W2547286628 creator A5084396601 @default.
• W2547286628 date "2015-12-03" @default.
• W2547286628 modified "2023-10-02" @default.
• W2547286628 title "Knockdown of HCK Reduces Cell Death and Erythroid Differentiation in Human CD34+ Hematopoietic Progenitor Cells" @default.
• W2547286628 doi "https://doi.org/10.1182/blood.v126.23.2860.2860" @default.
• W2547286628 hasPublicationYear "2015" @default.
• W2547286628 type Work @default.
• W2547286628 sameAs 2547286628 @default.
• W2547286628 citedByCount "0" @default.
• W2547286628 crossrefType "journal-article" @default.
• W2547286628 hasAuthorship W2547286628A5005491305 @default.
• W2547286628 hasAuthorship W2547286628A5010109904 @default.
• W2547286628 hasAuthorship W2547286628A5021576578 @default.
• W2547286628 hasAuthorship W2547286628A5037030579 @default.
• W2547286628 hasAuthorship W2547286628A5037865344 @default.
• W2547286628 hasAuthorship W2547286628A5052529953 @default.
• W2547286628 hasAuthorship W2547286628A5061724535 @default.
• W2547286628 hasAuthorship W2547286628A5062183952 @default.
• W2547286628 hasAuthorship W2547286628A5084396601 @default.
• W2547286628 hasConcept C10205521 @default.
• W2547286628 hasConcept C108636557 @default.
• W2547286628 hasConcept C109159458 @default.
• W2547286628 hasConcept C153911025 @default.
• W2547286628 hasConcept C173396325 @default.
• W2547286628 hasConcept C175818844 @default.
• W2547286628 hasConcept C179464577 @default.
• W2547286628 hasConcept C190232843 @default.
• W2547286628 hasConcept C201750760 @default.
• W2547286628 hasConcept C203014093 @default.
• W2547286628 hasConcept C2776090121 @default.
• W2547286628 hasConcept C2778461978 @default.
• W2547286628 hasConcept C28328180 @default.
• W2547286628 hasConcept C502942594 @default.
• W2547286628 hasConcept C54355233 @default.
• W2547286628 hasConcept C62478195 @default.
• W2547286628 hasConcept C81885089 @default.
• W2547286628 hasConcept C86803240 @default.
• W2547286628 hasConcept C8891405 @default.
• W2547286628 hasConcept C95444343 @default.
• W2547286628 hasConceptScore W2547286628C10205521 @default.
• W2547286628 hasConceptScore W2547286628C108636557 @default.
• W2547286628 hasConceptScore W2547286628C109159458 @default.
• W2547286628 hasConceptScore W2547286628C153911025 @default.
• W2547286628 hasConceptScore W2547286628C173396325 @default.
• W2547286628 hasConceptScore W2547286628C175818844 @default.
• W2547286628 hasConceptScore W2547286628C179464577 @default.
• W2547286628 hasConceptScore W2547286628C190232843 @default.
• W2547286628 hasConceptScore W2547286628C201750760 @default.
• W2547286628 hasConceptScore W2547286628C203014093 @default.
• W2547286628 hasConceptScore W2547286628C2776090121 @default.
• W2547286628 hasConceptScore W2547286628C2778461978 @default.
• W2547286628 hasConceptScore W2547286628C28328180 @default.
• W2547286628 hasConceptScore W2547286628C502942594 @default.
• W2547286628 hasConceptScore W2547286628C54355233 @default.
• W2547286628 hasConceptScore W2547286628C62478195 @default.
• W2547286628 hasConceptScore W2547286628C81885089 @default.
• W2547286628 hasConceptScore W2547286628C86803240 @default.
• W2547286628 hasConceptScore W2547286628C8891405 @default.
• W2547286628 hasConceptScore W2547286628C95444343 @default.
• W2547286628 hasLocation W25472866281 @default.
• W2547286628 hasOpenAccess W2547286628 @default.
• W2547286628 hasPrimaryLocation W25472866281 @default.
• W2547286628 hasRelatedWork W1603578230 @default.
• W2547286628 hasRelatedWork W2405320342 @default.
• W2547286628 hasRelatedWork W2518376518 @default.
• W2547286628 hasRelatedWork W2551034811 @default.
• W2547286628 hasRelatedWork W2566628926 @default.
• W2547286628 hasRelatedWork W2580728147 @default.
• W2547286628 hasRelatedWork W2586281078 @default.
• W2547286628 hasRelatedWork W2588171280 @default.
• W2547286628 hasRelatedWork W2594213988 @default.
• W2547286628 hasRelatedWork W2735852500 @default.
• W2547286628 hasRelatedWork W2746022227 @default.
• W2547286628 hasRelatedWork W2754937015 @default.
• W2547286628 hasRelatedWork W2786434754 @default.
• W2547286628 hasRelatedWork W2895922378 @default.
• W2547286628 hasRelatedWork W2980275429 @default.
• W2547286628 hasRelatedWork W2994262466 @default.
• W2547286628 hasRelatedWork W3042900979 @default.
• W2547286628 hasRelatedWork W3162613427 @default.
• W2547286628 hasRelatedWork W569496911 @default.
• W2547286628 hasRelatedWork W842833586 @default.
• W2547286628 isParatext "false" @default.
• W2547286628 isRetracted "false" @default.
• W2547286628 magId "2547286628" @default.
• W2547286628 workType "article" @default.